FY2030 Earnings Estimate for Agenus Issued By HC Wainwright

Agenus Inc. (NASDAQ:AGEN - Free Report) - HC Wainwright issued their FY2030 earnings estimates for shares of Agenus in a research note issued on Thursday, January 15th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will earn $0.34 per share for the year. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.55) per share.Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Agenus in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $14.50.Check Out Our Latest Stock Analysis on AGENAgenus Stock Down 9.2%NASDAQ:AGEN opened at $3.34 on Monday. The company has a market cap of $113.59 million, a P/E ratio of -1.57 and a beta of 1.58. The firm's 50 day moving average is $3.90 and its two-hundred day moving average is $4.42. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34. Agenus (NASDAQ:AGEN - Get Free Report) last released its earnings results on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.63 by ($0.69). The company had revenue of $30.24 million for the quarter, compared to analyst estimates of $80.39 million. Institutional Trading of AgenusSeveral large investors have recently added to or reduced their stakes in AGEN. Invesco Ltd. purchased a new position in Agenus in the first quarter valued at about $88,000. AQR Capital Management LLC grew its stake in shares of Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock valued at $664,000 after buying an additional 427,604 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Agenus in the first quarter valued at about $58,000. Strs Ohio purchased a new stake in shares of Agenus during the 1st quarter valued at about $214,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in Agenus during the 2nd quarter worth approximately $85,000. 61.46% of the stock is currently owned by institutional investors and hedge funds. About Agenus (Get Free Report)Agenus, Inc NASDAQ: AGEN is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies. Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.Featured ArticlesFive stocks we like better than AgenusElon Taking SpaceX Public! $100 Pre-IPO Opportunity!How a Family Trust May Be Able To Help Preserve Your WealthA U.S. “birthright” claim worth trillions - activated quietly“Fed Proof” Your Bank Account with THESE 4 Simple StepsNEW LAW: Congress Approves Setup For Digital Dollar? This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Agenus Right Now?Before you consider Agenus, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here